Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Core Insights - Acrivon Therapeutics is advancing ACR-2316, a selective dual WEE1 and PKMYT1 inhibitor, demonstrating strong preclinical activity and designed using the AP3 platform for enhanced single-agent efficacy [1][2] - The company will present data at the AACR Annual Meeting in April 2024, showcasing the broad applicability of its AP3 technology and its potential to address drug resistance mechanisms [2][3] Company Overview - Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, utilizing its proprietary AP3 platform to match treatments to patients based on tumor sensitivity [1][6] - The AP3 platform measures compound-specific effects on tumor cell protein signaling networks and drug resistance mechanisms, facilitating drug design optimization and patient identification for specific therapies [6] Pipeline and Development - Acrivon's lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial with Fast Track designation from the FDA for platinum-resistant ovarian or endometrial cancer [6] - ACR-2316 is the first fully internally-discovered candidate from Acrivon, generated through co-crystallography-based drug design, aimed at overcoming limitations of existing WEE1 and PKMYT1 inhibitors [2][6] Upcoming Presentations - Acrivon will present two key datasets at the AACR Annual Meeting: one on ACR-2316's design and efficacy, and another on the mechanism of resistance to ACR-368 and a combination treatment strategy [3][6]